Protocol Ledger

NCT07204314 · Phase III · RECRUITING

A Study of Vortioxetine in Japanese Pediatric Patients With Major Depressive Disorder

Interventional Phase III clinical trial protocol NCT07204314 sponsored by Takeda in Neurology, Psychiatry, and Pain, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-10-01 Enrollment: 180 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07204314
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)180 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07204314
Protocol FieldVerified Registry Value
NCT IdentifierNCT07204314
Consolidated Lead SponsorTakeda
Therapeutic Condition CohortNeurology, Psychiatry, and Pain
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment180 participants (ESTIMATED)
Registered Start Date2025-10-01
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07204314
Hospital Research SiteLocationSite Profile
Nagoya City University HospitalNagoya, JapanOpen Hospital Dossier ->
Hokkaido University HospitalSapporo, JapanOpen Hospital Dossier ->
Tohoku University HospitalSendai, JapanOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Takeda across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Neurology, Psychiatry, and Pain Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI